Cipemastat
![]() | |
Names | |
---|---|
Preferred IUPAC name
(2R,3R)-3-(Cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
IUPHAR/BPS
|
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H36N4O5 | |
Molar mass | 436.553 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
![]() ![]() ![]() | |
Infobox references | |
Cipemastat (rINN, also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent.[1] It is being developed by Roche.
References[]
- ^ Hemmings F, Farhan M, Rowland J, Banken L, Jain R (2001). "Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis". Rheumatology (Oxford). 40 (5): 537–43. doi:10.1093/rheumatology/40.5.537. PMID 11371662.
Categories:
- Hydantoins
- Hydroxamic acids
- Matrix metalloproteinase inhibitors
- Musculoskeletal system drug stubs